Genentech stops Erivedge IPF study before it starts

Genentech suspended patient recruitment for a Phase II clinical trial testing the hedgehog pathway inhibitor Erivedge (vismodegib) in the treatment of idiopathic pulmonary fibrosis (IPF) before the trial began enrolling patients.